Indivior PLC Ordinary Shares (INDV) - Total Liabilities
Based on the latest financial reports, Indivior PLC Ordinary Shares (INDV) has total liabilities worth $1.62 Billion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Indivior PLC Ordinary Shares - Total Liabilities Trend (2016–2024)
This chart illustrates how Indivior PLC Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Indivior PLC Ordinary Shares to evaluate short-term liquidity relative to the company's equity base.
Indivior PLC Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of Indivior PLC Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Titan Cement International SA
BR:TITC
|
Belgium | €1.37 Billion |
|
Antar Chile
SN:ANTARCHILE
|
Chile | CL$17.00 Billion |
|
Welspun Corp Limited
NSE:WELCORP
|
India | Rs78.24 Billion |
|
PT Alamtri Resources Indonesia Tbk
JK:ADRO
|
Indonesia | Rp1.42 Billion |
|
NBTM New Materials Group Co Ltd
SHG:600114
|
China | CN¥3.84 Billion |
|
AUMOVIO N
XETRA:AMV0
|
Germany | €9.56 Billion |
|
Union Semiconductor (Hefei) Co. Ltd. A
SHG:688403
|
China | CN¥1.02 Billion |
|
Hangzhou Hangyang Co Ltd
SHE:002430
|
China | CN¥14.46 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Indivior PLC Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see INDV market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -7.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Indivior PLC Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Indivior PLC Ordinary Shares (2016–2024)
The table below shows the annual total liabilities of Indivior PLC Ordinary Shares from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.67 Billion | -14.52% |
| 2023-12-31 | $1.95 Billion | +12.97% |
| 2022-12-31 | $1.73 Billion | +6.24% |
| 2021-12-31 | $1.63 Billion | +12.20% |
| 2020-12-31 | $1.45 Billion | +0.42% |
| 2019-12-31 | $1.44 Billion | -2.57% |
| 2018-12-31 | $1.48 Billion | -10.08% |
| 2017-12-31 | $1.65 Billion | +9.51% |
| 2016-12-31 | $1.50 Billion | -- |
About Indivior PLC Ordinary Shares
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more